EN
KRHC-101
[ HC-101 ] 전이암 및 항암제 내성암 세포 내
세포신호전달의 특이적 억제
| 표적 단백질 | 물질명 | 적응증 | 진행사항 |
|---|---|---|---|
| Receptor A | HC-101 | 전이성 난소암 |
전(비)임상 단계 (`25년 임상 1상 진입 목표) |
CHARACTERISTICS
-
First-in-class innovative anti-cancer drug based on Aptamer
-
New MOA based on specific signal transduction inhibitor for metastatic cancer
-
Unmet medical demand for ovarian cancer
MoA(Mode of Action mechanism)
Inducing metastatic cancer cell death by inhibiting signal transmission interaction
